<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PRF</journal-id>
<journal-id journal-id-type="hwp">spprf</journal-id>
<journal-id journal-id-type="nlm-ta">Perfusion</journal-id>
<journal-title>Perfusion</journal-title>
<issn pub-type="ppub">0267-6591</issn>
<issn pub-type="epub">1477-111X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0267659112456894</article-id>
<article-id pub-id-type="publisher-id">10.1177_0267659112456894</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>In vitro clearance of dexmedetomidine in extracorporeal membrane oxygenation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wagner</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff1-0267659112456894">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pasko</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff2-0267659112456894">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Phillips</surname><given-names>K</given-names></name>
<xref ref-type="aff" rid="aff3-0267659112456894">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Waldvogel</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff4-0267659112456894">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Annich</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff5-0267659112456894">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0267659112456894"><label>1</label>Pharmacy/Anesthesiology, University of Michigan Hospitals and Health Systems, Ann Arbor, MI, USA</aff>
<aff id="aff2-0267659112456894"><label>2</label>C&amp;W Administration, University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA</aff>
<aff id="aff3-0267659112456894"><label>3</label>Geriatric Research Education and Clinical Center, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA</aff>
<aff id="aff4-0267659112456894"><label>4</label>Extracorporeal Life Support, University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA</aff>
<aff id="aff5-0267659112456894"><label>5</label>Pediatric Critical Care Medicine, University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA</aff>
<author-notes>
<corresp id="corresp1-0267659112456894">Deborah Wagner 1540 E. Hospital Dr. 4-911 Mott Hosptial Ann Arbor Michigan 48109-4245, USA Email: <email>debbiew@umich.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>1</issue>
<fpage>40</fpage>
<lpage>46</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Dexmedetomidine (DMET) is a useful agent for sedation, both alone and in combination with other agents, in critically ill patients, including those on extracorporeal membrane oxygenation (ECMO) therapy. The drug is a clonidine-like derivative with an 8-fold greater specificity for the alpha 2-receptor while maintaining respiratory and cardiovascular stability. An in vitro ECMO circuit was used to study the effects of both “new” and “old” membrane oxygenators on the clearance of dexmedetomidine over the course of 24 hours. Once primed, the circuit was dosed with 840 μg of dexmedetomidine for a final concentration of 0.9 μg/ml. Serial samples, both pre- and post-oxygenator, were taken at 5, 60, 360, and 1440 minutes. Concentrations of the drug were expressed as a percentage of the original concentration remaining at each time point, both for new and old circuits. The new circuits were run at a standard flow for 24 hours, after which time the circuit was considered old and re-dosed with dexmedetomidine and the trial repeated. Results show that dexmedetomidine losses occur early in the circuits and then continue to decline. Initial losses in the first hour were 11+-65% and 59-73% pre- and post-oxygenator in the new circuit and 36-50% and 42-72% in the old circuit. The clearance of the drug through the membrane oxygenator exhibits no statistical difference between pre and post or new and old circuits. Dexmedetomidine can be expected to exhibit concentration changes during ECMO therapy. This effect appears to be more related to adsorption to the polyvinyl chloride (PVC) tubing rather than the membrane oxygenator. Dosage adjustments during dexmedetomidine administration during ECMO therapy may be warranted in order to maintain adequate serum concentrations and, hence, the desired degree of sedation.*(Lack of equilibrium)</p>
</abstract>
<kwd-group>
<kwd>extracorporeal membrane oxygenation</kwd>
<kwd>dexmedetomidine</kwd>
<kwd>clearance</kwd>
<kwd>in vitro</kwd>
<kwd>sedation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0267659112456894" sec-type="intro">
<title>Introduction</title>
<p>Extracorporeal life support (ECLS) initially was introduced in the late 1970s for the treatment of neonatal respiratory failure.<sup><xref ref-type="bibr" rid="bibr1-0267659112456894">1</xref></sup> Today, extracorporeal membrane oxygenation (ECMO) is used, both in adults and pediatrics, for respiratory and cardiac failure, with the majority of use occurring still in neonates and pediatrics. The Extracorporeal Life Support Organization (ELSO) has collected data on over 40,000 patients worldwide who have been treated with ECMO, the majority being in the neonatal and pediatric age range; however, increasing numbers of older children and adults are also utilizing the therapy. Recent trends in ECMO therapy display a shift toward increased mobilization in conscious patients while awaiting transplantation or implantation of medical assist devices. While on ECMO, patients must be refrained from excessive movement that may risk disruption of the ECMO lines and tubes. Disconnection can result in life-threatening events and, hence, sedation is often required in the patient throughout ECMO cannulation.<sup><xref ref-type="bibr" rid="bibr2-0267659112456894">2</xref></sup> Various agents, such as benzodiazepines and propofol, have been a standard of care for sedation, but not without issue. Benzodiazepines can often induce respiratory depression and propofol has been associated with the development of propofol syndrome with long-term use.<sup><xref ref-type="bibr" rid="bibr3-0267659112456894">3</xref></sup> This is in addition to opioid therapy, which is often also required. Recent interest has emerged relative to the potential use of dexmedetomidine in this patient population.</p>
<p>Dexmedetomidine (DMET) is a potent, selective alpha 2-adrenergic agonist with 7-10 times the affinity for the alpha 2-receptors than clonidine.<sup><xref ref-type="bibr" rid="bibr4-0267659112456894">4</xref><xref ref-type="bibr" rid="bibr5-0267659112456894"/><xref ref-type="bibr" rid="bibr6-0267659112456894"/>-<xref ref-type="bibr" rid="bibr7-0267659112456894">7</xref></sup> It is an imidazole derivative with a volume of distribution of 1.0 L/kg, both in pediatrics and adults, as well as being highly lipophilic.<sup><xref ref-type="bibr" rid="bibr8-0267659112456894">8</xref>,<xref ref-type="bibr" rid="bibr9-0267659112456894">9</xref></sup> More specifically, DMET demonstrates a pre-synaptic activation of alpha 2-adrenoreceptors, resulting in inhibition of norepinephrine and epinephrine and the termination of pain signals, as well as post-synaptic activation, causing decreases in heart rate and blood pressure. Not only does it produce sedation without amnesia, but induces sedation similar to non-rapid eye movement. Its two primary sites of action are in the brain stem in the locus coeruleus and in the dorsal horn ganglia. Inhibition of sympathetic outflow from the locus coeruleus increases the firing of inhibitory neurons. It produces reliable sedation and analgesia in a variety of settings, with a lower risk of respiratory depression than other alternatives.<sup><xref ref-type="bibr" rid="bibr4-0267659112456894">4</xref></sup>,<sup><xref ref-type="bibr" rid="bibr10-0267659112456894">10</xref><xref ref-type="bibr" rid="bibr11-0267659112456894"/><xref ref-type="bibr" rid="bibr12-0267659112456894"/>-<xref ref-type="bibr" rid="bibr13-0267659112456894">13</xref></sup> It has a profound opioid-sparing effect of up to 50%, most likely due to its spinal cord site of action.<sup><xref ref-type="bibr" rid="bibr14-0267659112456894">14</xref></sup> Unlike traditional sedative agents like propofol, benzodiazepines, and etomidate, DMET is non-gabamimetic and can avoid immunologic dysfunction, particularly in patients at risk in the intensive care unit (ICU) setting of infectious complications. DMET preserves cardiovascular and respiratory function in conventional doses of 0.2-0.7 μg/kg/hr infusions. DMET use in pediatrics is off-label despite its use for surgical procedures, procedural sedation, and ICU sedation.</p>
<p>Chrysostomou et al. reviewed the use of DMET in pediatric patients who had undergone cardiac and thoracic surgery.<sup><xref ref-type="bibr" rid="bibr10-0267659112456894">10</xref></sup> They found that DMET was a safe and effective sedative and analgesic that had no adverse respiratory events and displayed the unique property of effective sedation while, at the same time, making them easily arousable. The drug was well tolerated in infants and neonates, both in intubated and non-intubated patients. Another study by Berkenbosch, in 2005, looked at its use for sedation in non-invasive procedures in children.<sup><xref ref-type="bibr" rid="bibr11-0267659112456894">11</xref></sup> In addition to providing minimal anxiety and disorientation upon falling asleep and recovery, the drug was effective both, on its own and when used as a rescue agent. Tobias, et al. have shown DMET to be as equally effective as midazolam when used as a sedative, with significant decreases in supplemental benzodiazepine and opioid requirements.<sup><xref ref-type="bibr" rid="bibr12-0267659112456894">12</xref></sup> Hypotension and/or bradycardia requiring clinical intervention may occur.<sup><xref ref-type="bibr" rid="bibr12-0267659112456894">12</xref>,<xref ref-type="bibr" rid="bibr14-0267659112456894">14</xref>,<xref ref-type="bibr" rid="bibr15-0267659112456894">15</xref></sup></p>
<p>Quantitative assays for the analysis of plasma concentrations in vivo are not available and its small concentrations make plasma volumes too large for routine blood sampling in small newborns and infants.<sup><xref ref-type="bibr" rid="bibr16-0267659112456894">16</xref></sup> Use of a liquid chromatography-tandem mass spec (LC-MS/MS) assay using tolazoline as an internal standard has demonstrated the coefficient of variation (CV) between 1.04-6.84% with the % CV between 90.2-100.8%. An overall recovery was 76.6-78.3% in plasma.<sup><xref ref-type="bibr" rid="bibr17-0267659112456894">17</xref></sup> Dexmedetomidine has shown no degradation at 65 days of storage between 0-20°C, with no changes occurring between freeze/thaw cycles.<sup><xref ref-type="bibr" rid="bibr16-0267659112456894">16</xref></sup> Numerous obstacles exist in achieving proper serum levels of medications in the ECMO population.<sup><xref ref-type="bibr" rid="bibr18-0267659112456894">18</xref></sup> Administration of sedatives and analgesics during ECMO is challenging, as one must account for the increased volume of distribution in the circuit as well as the adsorption and binding of the drug to the oxygenator, heat exchanger, and tubing, in addition to the age of the circuit.<sup><xref ref-type="bibr" rid="bibr19-0267659112456894">19</xref>,<xref ref-type="bibr" rid="bibr20-0267659112456894">20</xref></sup> It is thought that lipophilic drugs easily adsorb to the PVC tubing.<sup><xref ref-type="bibr" rid="bibr21-0267659112456894">21</xref>,<xref ref-type="bibr" rid="bibr22-0267659112456894">22</xref></sup> Additionally, neonates on ECMO display different pharmacokinetics from those on conventional therapy with agents such as gentamicin, rantidine, and bumetanide.<sup><xref ref-type="bibr" rid="bibr20-0267659112456894">20</xref></sup> Changes in serum protein concentrations and, therefore, protein binding, altered hepatic, renal and cerebral blood flow, with corresponding organ dysfunction, can further complicate the issue.<sup><xref ref-type="bibr" rid="bibr23-0267659112456894">23</xref></sup> Due to these factors, it is thought that sedation requirements of patients on ECMO are 2-10 times greater than non-ECMO patients, an observation supported by a retrospective review by Mulla et al.<sup><xref ref-type="bibr" rid="bibr22-0267659112456894">22</xref></sup> Many studies have been conducted that consider the administration of sedative agents in ECMO.<sup><xref ref-type="bibr" rid="bibr23-0267659112456894">23</xref>,<xref ref-type="bibr" rid="bibr24-0267659112456894">24</xref></sup> In vitro analyses have demonstrated significant reductions in concentrations of morphine, lorazepam, and midazolam in the ECMO circuits.<sup><xref ref-type="bibr" rid="bibr19-0267659112456894">19</xref>,<xref ref-type="bibr" rid="bibr25-0267659112456894">25</xref><xref ref-type="bibr" rid="bibr26-0267659112456894"/>-<xref ref-type="bibr" rid="bibr27-0267659112456894">27</xref></sup> Conversely, an in vivo experiment by Geiduschek et al. found there to be no significant difference in morphine concentration over time when samples were taken from multiple sites within the circuits of five ECMO patients.<sup><xref ref-type="bibr" rid="bibr28-0267659112456894">28</xref></sup> Up to 50% of lorazepam and 40% of morphine is extracted by the PVC tubing and membrane oxygenator.<sup><xref ref-type="bibr" rid="bibr27-0267659112456894">27</xref></sup> DMET is a small molecule, being 94% protein bound, similar to adults, with a large volume of distribution, 1.0 L/kg, and might be thought to be extracted.<sup><xref ref-type="bibr" rid="bibr8-0267659112456894">8</xref></sup> Priming volumes also may differ between various oxygenators, which could contribute to changes in the volume of distribution of medications; however, probably to a small degree.<sup><xref ref-type="bibr" rid="bibr29-0267659112456894">29</xref></sup> Drugs with a large volume of distribution lose less drug than those with a smaller volume.<sup><xref ref-type="bibr" rid="bibr19-0267659112456894">19</xref></sup></p>
<p>Because ECMO circuits can be used for up to several weeks, an additional problem relative to the age of the circuit also arises. Conflicting information exists as to whether the “new” or “old” circuits extract more drug.<sup><xref ref-type="bibr" rid="bibr18-0267659112456894">18</xref>,<xref ref-type="bibr" rid="bibr19-0267659112456894">19</xref>,<xref ref-type="bibr" rid="bibr22-0267659112456894">22</xref>,<xref ref-type="bibr" rid="bibr24-0267659112456894">24</xref>,<xref ref-type="bibr" rid="bibr27-0267659112456894">27</xref></sup> Some studies have found that circuits that have been used for a few days have a lesser extent of decreased drug concentration due to adsorption.<sup><xref ref-type="bibr" rid="bibr19-0267659112456894">19</xref>,<xref ref-type="bibr" rid="bibr27-0267659112456894">27</xref></sup> This effect probably has to do with a priming effect on the tubing by the medication. Other studies have found that drug losses in “old” circuits are more significant. Quadrox-D® oxygenators by Maquet (Hirrlingen, Germany) are of a hollow-fiber membrane type, composed of polymethylpentene. The effects of this membrane on the clearance of commonly used agents for sedation and/or analgesia are unknown. Drug adsorption can also occur in to the polyvinyl chloride tubing used in the circuit.<sup><xref ref-type="bibr" rid="bibr22-0267659112456894">22</xref></sup> It has been reported with other lipophilic drugs, such as diazepam, that adsorption to the PVC tubing is affected by both the flow rate and the length of the tubing. Hence, flow rates in the ECMO circuit, depending on the patient’s age, could affect the adsorption of lipophilic agents, including dexmedetomidine.<sup><xref ref-type="bibr" rid="bibr30-0267659112456894">30</xref></sup> Lastly, Tarvainen et al. showed that changes in ionization of dexmedetomidine due to pH changes had no effect on adsorption to polygrafted polymembranes, suggesting that an equilibrium is established between the adsorption and binding sites on the tubing.<sup><xref ref-type="bibr" rid="bibr31-0267659112456894">31</xref></sup> Pharmacokinetic studies of doses of 0.5 μg/kg have yielded plasma concentrations in the range of 822-855 μg/ml<sup><xref ref-type="bibr" rid="bibr32-0267659112456894">32</xref></sup> while the use of target-controlled infusion devices have demonstrated effects on intracranial pressure and coronary perfusion pressure at 600 pg/ml.<sup><xref ref-type="bibr" rid="bibr7-0267659112456894">7</xref></sup> Due to discrepancies in the literature, more studies, both in vitro and in vivo, are needed to fully assess the impact of ECMO on drug clearance as well as therapeutic concentrations.</p>
</sec>
<sec id="section2-0267659112456894" sec-type="methods">
<title>Methods</title>
<p>Using an in vitro model, an ECMO circuit, consisting of ¼” tubing, a Quadrox-D® oxygenator (MaquetSafeline, Maquet, Hirrlingen, Germany), and a roller pump (Baxter Century, Baxter International Inc., Deerfield, IL, USA) was first prepared by crystalloid priming with Normosol-R. Albumin 25% (15 ml) was added to the prime and allowed to circulate for five minutes. Two units of expired human packed red blood cells (PRBC) were prepared by adding 100 units of heparin, 50 cc tromethamine (THAM), 400 mg calcium chloride (CaCl<sub>2</sub>), 10 mEq. sodium bicarbonate (NaHCO<sub>3</sub>), and 50 cc expired human plasma to each unit. After removing the Normosol-R from the priming reservoir, both units of PRBC were added and the ECMO circuit was, subsequently, “blood primed”. The blood prime was allowed to circulate at 600 ml/minute. The oxygenator was ventilated (sweep) at 300 ml/minute, using a gas mix of 95% oxygen and 5% CO<sub>2</sub>. This ensured a perfusate pCO<sub>2</sub> in the normal physiologic range (35-45 mmHg). Perfusate pH was maintained between 7.25 and 7.45, administering NaHCO<sub>3</sub> as necessary. Ionized calcium was maintained between 0.8 and 1.3 mmol/L, administering CaCl<sub>2</sub> as necessary. Blood gas/electrolyte analysis was performed with an Abbott i-STAT1 portable clinical analyzer (Abbott Labs, Abbott Park, IL, USA). Perfusate temperature was managed by perfusate exposure to oxygenator heat exchange fibers with the water bath temperature set at 37 degrees Celsius (Cincinnati Sub-Zero Products Inc., Cincinnati, OH, USA). Continuous infusions of DMET, simulated by recirculation of the blood in the circuit, were based on calculations for a circuit volume of approximately 930 ml. Eight hundred and forty micrograms of dexmedetomidine was added to the circuit to mimic a plasma concentration of 0.9μg/ml.<sup><xref ref-type="bibr" rid="bibr4-0267659112456894">4</xref>,<xref ref-type="bibr" rid="bibr9-0267659112456894">9</xref></sup> ECMO circuit blood flow was maintained at 300 ml/min and the blood primed with DMET allowed to equilibriate for 5-10 minutes. Blood gas and electrolyte parameters, as described earlier, were maintained by periodic blood gas/electrolyte analysis. Blood samples for DMET analysis were drawn from two sites, pre- and post-oxygenator, after removal of 0.6 ml of waste blood in the tubing. Samples were taken from each site at time 0 (5minutes), 1 hour (60 minutes), 6 hours (360 minutes), and 24 hours (1440 minutes). Samples were collected in red top Vacutainer tubes (Becton Dickinson and Co., Franklin Lakes, MJ, USA), and plasma separated using a Beckman Spinchron (Beckman Coulter, Indianapolis, IN, USA) centrifuge at 2700 rpm for 12-15minutes and then frozen at -80<sup>o</sup>C until analysis. After 24 hours, the circuit became the “old” circuit and the process repeated, with another loading dose of DMET added. Samples were analyzed by the Department of Clinical Pharmacology and Therapeutics at the Children’s Hospital of Philadelphia, using a liquid chromatography-tandem mass spectrometry (LC-MS/MS). The assay has a lower limit of 5 pg/ml with a linear range of 5-1500 pg/ml and is able to detect dexmedetomidine in small samples of human plasma.<sup><xref ref-type="bibr" rid="bibr17-0267659112456894">17</xref></sup></p>
</sec>
<sec id="section3-0267659112456894" sec-type="results">
<title>Results</title>
<p>The results expressed are shown in <xref ref-type="table" rid="table1-0267659112456894">Tables 1</xref><xref ref-type="table" rid="table2-0267659112456894"/>-<xref ref-type="table" rid="table3-0267659112456894">3</xref> for time periods of 5, 60, 360, and 1440 minutes for both new and old circuits and pre- and post-oxygenator drug concentrations. In all circuits, both new and old, concentrations of dexmedetomidine declined over the entire 24 hour time period. Within the first hour in the new circuit DMET, concentration decreased 11+-65% and 59-73% pre- and post-membrane oxygenator, respectively. In the old circuit, decreases in concentration pre- and post-membrane oxygenator were 36-50% and 42-72% (<xref ref-type="table" rid="table1-0267659112456894">Table 1</xref>). Over the 24-hour time period, the total percentage of drug loss in the circuits pre-membrane oxygenator was 76-89% in the new and 67-88% in the old while post-membrane oxygenator losses were 67.4-93% in the new and 77-82% in the old (<xref ref-type="table" rid="table1-0267659112456894">Table 1</xref>). There was no statistical difference in drug loss at 24 hours between the new and old circuits nor pre- to post-membrane oxygenator concentrations, p&lt;0.05 (<xref ref-type="table" rid="table2-0267659112456894">Table 2</xref>,<xref ref-type="table" rid="table3-0267659112456894">3</xref>) as concentrations declined consistently over time. Variability within and amongst samples may be due to a lack of drug equilibrium in the circuits, especially at T= 5minutes where the drug may have not been fully distributed in the circuit. (+lack of equilibrium)</p>
<table-wrap id="table1-0267659112456894" position="float">
<label>Table 1.</label>
<caption><p>Percent (%) drug remaining over time</p></caption>
<graphic alternate-form-of="table1-0267659112456894" xlink:href="10.1177_0267659112456894-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="left">Time = 0</th>
<th align="left">T = 5 Min</th>
<th align="left">T = 60 Min</th>
<th align="left">T = 360 Min</th>
<th align="left">T = 1440 Min</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>New</bold></td>
<td>Pre Trial A</td>
<td>100</td>
<td>53.89</td>
<td>34.67 (65%)</td>
<td>27.78</td>
<td>11.11</td>
</tr>
<tr>
<td/>
<td>B</td>
<td>100</td>
<td>157.78 <sup><xref ref-type="table-fn" rid="table-fn1-0267659112456894">*</xref></sup></td>
<td>89.00 (11<sup><xref ref-type="table-fn" rid="table-fn1-0267659112456894">*</xref></sup>)</td>
<td>40.22</td>
<td>21.00</td>
</tr>
<tr>
<td/>
<td>C</td>
<td>100</td>
<td>75.33</td>
<td>59.22</td>
<td>14.56</td>
<td>24.11</td>
</tr>
<tr>
<td/>
<td>Post Trial A</td>
<td>100</td>
<td>57.56</td>
<td>40.89 (59%)</td>
<td>27.44</td>
<td>32.56</td>
</tr>
<tr>
<td/>
<td>B</td>
<td>100</td>
<td>49.78</td>
<td>32.61</td>
<td>10.83</td>
<td>7.11</td>
</tr>
<tr>
<td/>
<td>C</td>
<td>100</td>
<td>37.44</td>
<td>27.44 (73%)</td>
<td>11.62</td>
<td>8.13</td>
</tr>
<tr>
<td><bold>Old</bold></td>
<td>Pre Trial A</td>
<td>100</td>
<td>69.22</td>
<td>50.00 (50%)</td>
<td>28.44</td>
<td>12.22</td>
</tr>
<tr>
<td/>
<td>B</td>
<td>100</td>
<td>121.11 <sup><xref ref-type="table-fn" rid="table-fn1-0267659112456894">*</xref></sup></td>
<td>58.89</td>
<td>56.78</td>
<td>31.78</td>
</tr>
<tr>
<td/>
<td>C</td>
<td>100</td>
<td>221.11 <sup><xref ref-type="table-fn" rid="table-fn1-0267659112456894">*</xref></sup></td>
<td>64.00 (36%)</td>
<td>58.56</td>
<td>32.89</td>
</tr>
<tr>
<td/>
<td>Post Trial A</td>
<td>100</td>
<td>76.33</td>
<td>58.00 (42%)</td>
<td>34.44</td>
<td>18.11</td>
</tr>
<tr>
<td/>
<td>B</td>
<td>100</td>
<td>39.33</td>
<td>27.67 (72%)</td>
<td>23.78</td>
<td>23.17</td>
</tr>
<tr>
<td/>
<td>C</td>
<td>100</td>
<td>64.94</td>
<td>36.44</td>
<td>20.33</td>
<td>19.22</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0267659112456894">
<label>*</label>
<p>Lack of equilibrium in circuit</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0267659112456894" position="float">
<label>Table 2.</label>
<caption><p>New to old circuit: concentration changes</p></caption>
<graphic alternate-form-of="table2-0267659112456894" xlink:href="10.1177_0267659112456894-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="left" colspan="2">Pre-membrane Oxygenatorc<sup>c</sup><hr/></th>
<th align="left" colspan="3">Post-membrane Oxygenatord<sup>d</sup><hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="left">Mean</th>
<th align="left">St Dev</th>
<th align="left">Mean</th>
<th align="left">St Dev</th>
<th align="left">N</th>
</tr>
</thead>
<tbody>
<tr>
<td>T=0</td>
<td>New</td>
<td>900.00</td>
<td>0.00</td>
<td>900.00</td>
<td>0.00</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Old</td>
<td>900.00</td>
<td>0.00</td>
<td>900.00</td>
<td>0.00</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Total</td>
<td>900.00</td>
<td>0.00</td>
<td>900.00</td>
<td>0.00</td>
<td>6</td>
</tr>
<tr>
<td>T=5 Min</td>
<td>New</td>
<td>861.00</td>
<td>493.63</td>
<td>434.50</td>
<td>91.00</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Old</td>
<td>1234.33</td>
<td>694.84</td>
<td>542.00</td>
<td>170.61</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Total</td>
<td>1047.67</td>
<td>576.54</td>
<td>488.25</td>
<td>135.73</td>
<td>6</td>
</tr>
<tr>
<td>T=60 Min</td>
<td>New</td>
<td>548.67</td>
<td>244.88</td>
<td>303.00</td>
<td>61.00</td>
<td>3</td>
</tr>
<tr>
<td>(1hr)</td>
<td>Old</td>
<td>518.67</td>
<td>63.76</td>
<td>366.33</td>
<td>140.48</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Total</td>
<td>533.67</td>
<td>160.88</td>
<td>334.67</td>
<td>102.89</td>
<td>6</td>
</tr>
<tr>
<td>T=360 Min</td>
<td>New</td>
<td>238.68</td>
<td>116.29</td>
<td>149.67</td>
<td>84.39</td>
<td>3</td>
</tr>
<tr>
<td>(6hrs)</td>
<td>Old</td>
<td>431.33</td>
<td>152.05</td>
<td>235.67</td>
<td>66.21</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Total</td>
<td>335.00</td>
<td>160.61</td>
<td>192.67</td>
<td>82.59</td>
<td>6</td>
</tr>
<tr>
<td>T=1440 Min</td>
<td>New</td>
<td>168.67</td>
<td>61.09</td>
<td>144.00</td>
<td>129.15</td>
<td>3</td>
</tr>
<tr>
<td>(24hrs)</td>
<td>Old</td>
<td>230.67</td>
<td>104.62</td>
<td>181.33</td>
<td>23.63</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Total</td>
<td>199.67</td>
<td>83.81</td>
<td>162.67</td>
<td>85.52</td>
<td>6</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table3-0267659112456894" position="float">
<label>Table 3.</label>
<caption><p>Pre-to post-membrane oxygenator drug concentration changes</p></caption>
<graphic alternate-form-of="table3-0267659112456894" xlink:href="10.1177_0267659112456894-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Pre vs Post</th>
<th align="left" colspan="3">New<sup>a</sup><hr/></th>
<th align="left" colspan="3">Old<sup>b</sup><hr/></th>
</tr>
<tr>
<th align="left">Time 0</th>
<th align="left">Pre vs Post</th>
<th align="left">Mean</th>
<th align="left">Std Deviation</th>
<th align="left">Mean</th>
<th align="left">Std Dev</th>
<th align="left">N</th>
</tr>
</thead>
<tbody>
<tr>
<td/>
<td>Pre</td>
<td>900.00</td>
<td>0.00</td>
<td>900.00</td>
<td>0.00</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Post</td>
<td>900.00</td>
<td>0.00</td>
<td>900.00</td>
<td>0.00</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Total</td>
<td>900.00</td>
<td>0.00</td>
<td>900.00</td>
<td>0.00</td>
<td>6</td>
</tr>
<tr>
<td>5 Min</td>
<td>Pre</td>
<td>861.00</td>
<td>493.63</td>
<td>1234.33</td>
<td>694.84</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Post</td>
<td>434.50</td>
<td>91.00</td>
<td>542.00</td>
<td>170.61</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Total</td>
<td>647.75</td>
<td>394.15</td>
<td>888.17</td>
<td>590.39</td>
<td>6</td>
</tr>
<tr>
<td>60 Min</td>
<td>Pre</td>
<td>548.67</td>
<td>244.88</td>
<td>518.67</td>
<td>63.76</td>
<td>3</td>
</tr>
<tr>
<td>(1Hr)</td>
<td>Post</td>
<td>303.00</td>
<td>61.00</td>
<td>366.33</td>
<td>140.48</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Total</td>
<td>425.83</td>
<td>208.76</td>
<td>442.50</td>
<td>128.38</td>
<td>6</td>
</tr>
<tr>
<td>360 Min</td>
<td>Pre</td>
<td>238.67</td>
<td>116.29</td>
<td>431.33</td>
<td>152.05</td>
<td>3</td>
</tr>
<tr>
<td>(6Hrs)</td>
<td>Post</td>
<td>149.67</td>
<td>84.39</td>
<td>235.67</td>
<td>66.21</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Total</td>
<td>194.17</td>
<td>103.12</td>
<td>333.00</td>
<td>149.96</td>
<td>6</td>
</tr>
<tr>
<td>1440 Min</td>
<td>Pre</td>
<td>168.67</td>
<td>61.09</td>
<td>230.67</td>
<td>104.62</td>
<td>3</td>
</tr>
<tr>
<td>(24 Hrs)</td>
<td>Post</td>
<td>144.00</td>
<td>129.15</td>
<td>181.33</td>
<td>23.63</td>
<td>3</td>
</tr>
<tr>
<td/>
<td>Total</td>
<td>156.33</td>
<td>91.36</td>
<td>206.00</td>
<td>73.02</td>
<td>6</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Repeated measures analysis of variance (ANOVA) was used to analyze the data, with p&lt;0.05 considered statistically significant. The concentration of dexmedetomidine declined significantly over time in both new and old oxygenators, p=0.016c and p=0.019d, respectively (<xref ref-type="table" rid="table2-0267659112456894">Table 2</xref>). The concentrations pre- and post-membrane oxygenator between the new and old circuits were also not statistically significant, p=0.094a and p=0.090b, respectively (<xref ref-type="table" rid="table3-0267659112456894">Table 3</xref>). There were no differences in pre- to post-membrane oxygenator concentrations at any sampling time in the new or old membrane oxygenators, p=0.215 (new) and p=0.141 (old).</p>
</sec>
<sec id="section4-0267659112456894" sec-type="discussion">
<title>Discussion</title>
<p>The use of ECMO to provide lung recovery from a variety of diseases or surgery is complicated by the need to provide the patient with adequate analgesia, sedation and anxiolysis. Maintaining adequate sedation in patients undergoing ECMO therapy is critical, not only to ensure patient comfort, but also safety. The prevention of complications within the circuit is critical, such that it is imperative to ensure that physiologic stresses are minimized and potential disruption of the circuit is avoided. Current trends for analgesia have focused on the use of opioids such as morphine and fentanyl while sedation has traditionally used the benzodiazepines. Continuous prolonged use of these agents may promote the development of withdrawal, complicating the discontinuation of ECMO.<sup><xref ref-type="bibr" rid="bibr33-0267659112456894">33</xref>,<xref ref-type="bibr" rid="bibr34-0267659112456894">34</xref></sup> By utilizing other pharmacologic agents with potential opioid-sparing effects could be beneficial in this population. DMET is a new agent with non-gabamimetic action that displays potent sedative, analgesic and anxiolytic properties. It is unique in that it exhibits little respiratory depression and can maintain a random eye movement (REM)-like sleep while, at the same time, keeping patients arousable for neurologic assessment. Due to the lipophilic nature of the drug, it appears that, just like fentanyl, the drug is continuously lost in the circuit and does not reach a steady state concentration, unlike morphine.<sup><xref ref-type="bibr" rid="bibr35-0267659112456894">35</xref></sup> It is unknown whether or not larger than expected doses might be needed to obtain the desired level of sedation with DMET in patients on ECMO therapy.</p>
<p>This study is limited by the fact that sampling was only done pre- and post-oxygenator and not from the PVC tubing alone. It appears from the results that a consistent amount of dexmedetomidine is removed consistently over time, both pre- and post-membrane oxygenator, regardless of the age of the oxygenator. The confounding variable is that one would anticipate that the old filter would already be saturated with drug such that reloading the circuit would have no effect on further extraction of the drug. That, however, was not the case, as seen here in the old circuit where a significant drug loss was again seen at T=5 minutes and throughout the 24-hour time period. This would lead one to suspect that, perhaps, it is the PVC tubing and not the oxygenator that is impacting the removal of the drug, consistent with, perhaps, the pharmacokinetics of the drug and its lipophilicity. Additional clearance studies with the PVC tubing is necessary to determine the exact impact on the drug concentration. Obviously, as the length of the ECMO tubing increases, one would expect that the increased surface area would allow for more drug adsorption. This may cause variability, depending on the patient population and the design of the circuit. This could, potentially, be accommodated for by use of centrifugal rather than roller pumps, which would use a standard circuit set up regardless of patient size.<sup><xref ref-type="bibr" rid="bibr36-0267659112456894">36</xref></sup> Another factor to consider is the role that continuous renal replacement therapy (CRRT) circuits could play in relation to drug removal. It is not uncommon for ECMO patients to have some degree of acute renal insufficiency, ranging from risk to failure, according to the RIFLE and pRIFLE guidelines. Smith and colleagues revealed that the incidence of acute renal failure (ARF) was 71.7% in 48 pediatric cardiac ECMO patients studied, and CRRT was initiated in 58.7% of the patients.<sup><xref ref-type="bibr" rid="bibr37-0267659112456894">37</xref></sup> Swaniker and colleagues found similar results in adult patients requiring EMCO: of 205 adult ECMO patients studied, ARF was found in 130 patients, 104 of them requiring CRRT.<sup><xref ref-type="bibr" rid="bibr38-0267659112456894">38</xref></sup> The removal of dexmedetomidine by CRRT should, theoretically, be small given the high protein binding in patients of 94%. Based upon this characteristic, dexemedetomidine should not be removed by any clinically significant amount via CRRT standard hemodiafilters, as sieving and saturation coefficients closely mimic protein binding in normal CRRT situations.</p>
<p>As dexmedetomidine is usually administered via a constant infusion rather than by bolus administration, one would suspect that no difference would be seen between a new and old oxygenator. This is explained by the results of this study. One should still be vigilant during the initial dosing of dexmedtomidine in patients on ECMO as plasma concentrations may initially decrease, leading to increasing rates of drug administration. This could, potentially, be eliminated by utilizing the bolus dose, often not administered due to rapidly occurring hypotension that may result in initial saturation of the circuit. ECMO also increases the volume of distribution of drugs due to its dilutional effect on plasma.<sup><xref ref-type="bibr" rid="bibr39-0267659112456894">39</xref></sup> This can cause changes in drug concentrations until equilibrium is established. Priming volumes should also be considered relative to the type of oxygenator used as this, too, may affect the volume of distribution, albeit to a smaller degree. It has been shown that significantly more midazolam is needed in the first 24 hours due to the increased volume and adsorption to the circuit. Maintenance doses may need to be reduced.<sup><xref ref-type="bibr" rid="bibr26-0267659112456894">26</xref></sup> Further in vivo studies with various circuit sizes are warranted to validate the in vitro model studied here.</p>
</sec>
<sec id="section5-0267659112456894" sec-type="conclusions">
<title>Conclusion</title>
<p>Data regarding the pharmacokinetics of drugs used during ECMO therapy highlight challenges to healthcare providers for maintaining adequate serum concentrations of drugs. Dexmedetomidine exhibits consistent clearance in the ECMO circuit, with most of the drug loss not attributable to the membrane oxygenator. Losses in the circuit, however, are consistent between old and new circuits, with the losses occurring throughout the 24-hour time frame. One cannot state with 100% confidence that the membrane oxygenator does not contribute to drug loss in the circuit; however, it is probably not the driving force at work. Loading doses, which are often not administered, might be considered useful in the initiation of dexmedetomidine therapy in ECMO patients due to the early loss of the drug. Further studies, both of PVC tubing and in vivo, should be performed to further define the clearance of the drug in ECMO patients, as well as the effects of protein binding, renal dysfunction, metabolic differences, and pathophysiological changes that occur in the critically ill patient.<sup><xref ref-type="bibr" rid="bibr40-0267659112456894">40</xref>,<xref ref-type="bibr" rid="bibr41-0267659112456894">41</xref></sup> In the meantime, careful consideration should be taken while administering DMET to patients on ECMO therapy. Increases in dose requirements may be directly related to either the ECMO circuit or altered pharmacokinetics of the drug, but not due to the development of tolerance to the agent. Dexmedetomidine offers an acceptable safety profile that may offer advantages over current options for sedation in patients receiving ECMO therapy.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of Interest Statement</label>
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0267659112456894">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartlett</surname><given-names>RH</given-names></name>
<name><surname>Roloff</surname><given-names>DW</given-names></name>
<name><surname>Cornell</surname><given-names>RG</given-names></name>
<name><surname>Andrews</surname><given-names>AF</given-names></name>
<name><surname>Dillon</surname><given-names>PW</given-names></name>
<name><surname>Zwischenberger</surname><given-names>JB</given-names></name>
</person-group>. <article-title>Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study</article-title>. <source>Pediatrics</source> <year>1985</year>; <volume>76</volume>: <fpage>479</fpage>–<lpage>487</lpage>.</citation>
</ref>
<ref id="bibr2-0267659112456894">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caron</surname><given-names>E</given-names></name>
<name><surname>Maguire</surname><given-names>DP</given-names></name>
</person-group>. <article-title>Current management of pain, sedation, and narcotic physical dependency of the infant on ECMO</article-title>. <source>J Perinat Neonatal Nurs</source> <year>1990</year>; <volume>4</volume>: <fpage>63</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr3-0267659112456894">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okamoto</surname><given-names>MP</given-names></name>
<name><surname>Kawaguchi</surname><given-names>DL</given-names></name>
<name><surname>Amin</surname><given-names>AN</given-names></name>
</person-group>. <article-title>Evaluation of propofol infusion syndrome in pediatric intensive care</article-title>. <source>Am J Health-System Pharmacy</source> <year>2003</year>; <volume>60</volume>: <fpage>2007</fpage>–<lpage>2014</lpage>.</citation>
</ref>
<ref id="bibr4-0267659112456894">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhana</surname><given-names>N</given-names></name>
<name><surname>Goa</surname><given-names>KL</given-names></name>
<name><surname>McClellan</surname><given-names>KJ</given-names></name>
</person-group>. <article-title>Dexmedetomidine</article-title>. <source>Drugs</source> <year>2000</year>; <volume>59</volume>: <fpage>263</fpage>–<lpage>268</lpage>; <comment>discussion</comment> <fpage>269</fpage>–<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr5-0267659112456894">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Virtanen</surname><given-names>R</given-names></name>
<name><surname>Savola</surname><given-names>JM</given-names></name>
<name><surname>Saano</surname><given-names>V</given-names></name>
<name><surname>Nyman</surname><given-names>L</given-names></name>
</person-group>. <article-title>Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist</article-title>. <source>Eur J Pharmacol</source> <year>1988</year>; <volume>150</volume>: <fpage>9</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr6-0267659112456894">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levanen</surname><given-names>J</given-names></name>
<name><surname>Makela</surname><given-names>ML</given-names></name>
<name><surname>Scheinin</surname><given-names>H</given-names></name>
</person-group>. <article-title>Dexmedetomidine premedication attenuates ketamine-induced cardiostimulatory effects and postanesthetic delirium</article-title>. <source>Anesthesiology</source> <year>1995</year>; <volume>82</volume>: <fpage>1117</fpage>–<lpage>1125</lpage>.</citation>
</ref>
<ref id="bibr7-0267659112456894">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tobias</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology</article-title>. <source>Pediatr Crit Care Med</source> <year>2007</year>; <volume>8</volume>: <fpage>115</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr8-0267659112456894">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petroz</surname><given-names>GC</given-names></name>
<name><surname>Sikich</surname><given-names>N</given-names></name>
<name><surname>James</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children</article-title>. <source>Anesthesiology</source> <year>2006</year>; <volume>105</volume>: <fpage>1098</fpage>–<lpage>1110</lpage>.</citation>
</ref>
<ref id="bibr9-0267659112456894">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Potts</surname><given-names>AL</given-names></name>
<name><surname>Anderson</surname><given-names>BJ</given-names></name>
<name><surname>Warman</surname><given-names>GR</given-names></name>
<name><surname>Lerman</surname><given-names>J</given-names></name>
<name><surname>Diaz</surname><given-names>SM</given-names></name>
<name><surname>Vilo</surname><given-names>S</given-names></name>
</person-group>. <article-title>Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis</article-title>. <source>Paediatr Anaesth</source> <year>2009</year>; <volume>19</volume>: <fpage>1119</fpage>–<lpage>1129</lpage>.</citation>
</ref>
<ref id="bibr10-0267659112456894">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chrysostomou</surname><given-names>C</given-names></name>
<name><surname>Di Filippo</surname><given-names>S</given-names></name>
<name><surname>Manrique</surname><given-names>AM</given-names></name>
<etal/>
</person-group>., <article-title>Use of dexmedetomidine in children after cardiac and thoracic surgery.[see comment]</article-title>. <source>Pediatric Critical Care Medicine</source> <year>2006</year>; <volume>7</volume>: <fpage>126</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr11-0267659112456894">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berkenbosch</surname><given-names>JW</given-names></name>
<name><surname>Wankum</surname><given-names>PC</given-names></name>
<name><surname>Tobias</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Prospective evaluation of dexmedetomidine for noninvasive procedural sedation in children.[see comment]</article-title>. <source>Pediatric Critical Care Medicine</source> <year>2005</year>; <volume>6</volume>: <fpage>435</fpage>–<lpage>439</lpage>; <comment>quiz 440</comment>.</citation>
</ref>
<ref id="bibr12-0267659112456894">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tobias</surname><given-names>JD</given-names></name>
<name><surname>Berkenbosch</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam</article-title>. <source>Southern Medical Journal</source> <year>2004</year>; <volume>97</volume>: <fpage>451</fpage>–<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr13-0267659112456894">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gertler</surname><given-names>R</given-names></name>
<name><surname>Brown</surname><given-names>HC</given-names></name>
<name><surname>Mitchell</surname><given-names>DH</given-names></name>
<name><surname>Silvius</surname><given-names>EN</given-names></name>
</person-group>. <article-title>Dexmedetomidine: a novel sedative-analgesic agent</article-title>. <source>BUMC Proceedings</source> <year>2001</year>; <volume>14</volume>: <fpage>13</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr14-0267659112456894">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Czaja</surname><given-names>AS</given-names></name>
<name><surname>Zimmerman</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>The use of dexmedetomidine in critically ill children</article-title>. <source>Pediatr Crit Care Med</source> <year>2009</year>; <volume>10</volume>: <fpage>381</fpage>–<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr15-0267659112456894">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wong</surname><given-names>J</given-names></name>
<name><surname>Steil</surname><given-names>GM</given-names></name>
<name><surname>Curtis</surname><given-names>M</given-names></name>
<name><surname>Papas</surname><given-names>A</given-names></name>
<name><surname>Zurakowski</surname><given-names>D</given-names></name>
<name><surname>Mason</surname><given-names>KP</given-names></name>
</person-group>. <article-title>Cardiovascular effects of dexmedetomidine sedation in children</article-title>. <source>Anesth Analg</source> <year>2012</year>; <volume>114</volume>: <fpage>193</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr16-0267659112456894">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ji</surname><given-names>QC</given-names></name>
<name><surname>Zhou</surname><given-names>JY</given-names></name>
<name><surname>Gonzales</surname><given-names>RJ</given-names></name>
<name><surname>Gage</surname><given-names>EM</given-names></name>
<name><surname>El-Shourbagy</surname><given-names>TA</given-names></name>
</person-group>. <article-title>Simultaneous quantitation of dexmedetomidine and glucuronide metabolites (G-Dex-1 and G-Dex-2) in human plasma utilizing liquid chromatography with tandem mass spectrometric detection</article-title>. <source>Rapid Communications in Mass Spectrometry</source> <year>2004</year>; <volume>18</volume>: <fpage>1753</fpage>–<lpage>1760</lpage>.</citation>
</ref>
<ref id="bibr17-0267659112456894">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>JI</given-names></name>
<name><surname>Su</surname><given-names>F</given-names></name>
<name><surname>Shi</surname><given-names>H</given-names></name>
<name><surname>Zuppa</surname><given-names>AF</given-names></name>
</person-group>. <article-title>Sensitive and specific liquid chromatography-tandem mass spectrometric method for the quantitation of dexmedetomidine in pediatric plasma</article-title>. <source>J Chromatogr B Analyt Technol Biomed Life Sci</source> <year>2007</year>; <volume>852</volume>: <fpage>195</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr18-0267659112456894">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mulla</surname><given-names>H</given-names></name>
<name><surname>Lawson</surname><given-names>G</given-names></name>
<name><surname>von Anrep</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation</article-title>. <source>Perfusion</source> <year>2000</year>; <volume>15</volume>: <fpage>21</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr19-0267659112456894">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dagan</surname><given-names>O</given-names></name>
<name><surname>Klein</surname><given-names>J</given-names></name>
<name><surname>Gruenwald</surname><given-names>C</given-names></name>
<name><surname>Bohn</surname><given-names>D</given-names></name>
<name><surname>Barker</surname><given-names>G</given-names></name>
<name><surname>Koren</surname><given-names>G</given-names></name>
</person-group>. <article-title>Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs</article-title>. <source>Ther Drug Monit</source> <year>1993</year>; <volume>15</volume>: <fpage>263</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr20-0267659112456894">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buck</surname><given-names>ML</given-names></name>
</person-group>. <article-title>Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates</article-title>. <source>Clin Pharmacokinet</source> <year>2003</year>; <volume>42</volume>: <fpage>403</fpage>–<lpage>417</lpage>.</citation>
</ref>
<ref id="bibr21-0267659112456894">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>T</given-names></name>
<name><surname>Uchida</surname><given-names>I</given-names></name>
<name><surname>Mashimo</surname><given-names>T</given-names></name>
</person-group>. <article-title>Sorptive loss of volatile and gaseous anesthetics from in vitro drug application systems</article-title>. <source>Anesth Analg</source> <year>2005</year>; <volume>100</volume>: <fpage>427</fpage>–<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr22-0267659112456894">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mulla</surname><given-names>H</given-names></name>
<name><surname>Lawson</surname><given-names>G</given-names></name>
<name><surname>Woodland</surname><given-names>ED</given-names></name>
<etal/>
</person-group>. <article-title>Effects of neonatal extracorporeal membrane oxygenation circuits on drug disposition</article-title>. <source>Current Therapeutic Research</source> <year>2000</year>; <volume>61</volume>: <fpage>838</fpage>–<lpage>848</lpage>.</citation>
</ref>
<ref id="bibr23-0267659112456894">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burda</surname><given-names>G and</given-names></name>
<name><surname>Trittenwein</surname><given-names>G</given-names></name>
</person-group>. <article-title>Issues of pharmacology in pediatric cardiac extracorporeal membrane oxygenation with special reference to analgesia and sedation</article-title>. <source>Artif Organs</source> <year>1999</year>; <volume>23</volume>: <fpage>1015</fpage>–<lpage>1019</lpage>.</citation>
</ref>
<ref id="bibr24-0267659112456894">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noerr</surname><given-names>B</given-names></name>
</person-group>. <article-title>ECMO and pharmacotherapy</article-title>.[<comment>see comment</comment>]. <source>Neonatal Netw</source> <year>1996</year>; <volume>15</volume>: <fpage>23</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr25-0267659112456894">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dagan</surname><given-names>O</given-names></name>
<name><surname>Klein</surname><given-names>J</given-names></name>
<name><surname>Bohn</surname><given-names>D</given-names></name>
<name><surname>Koren</surname><given-names>G</given-names></name>
</person-group>. <article-title>Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants</article-title>. <source>Crit Care Med</source> <year>1994</year>; <volume>22</volume>: <fpage>1099</fpage>–<lpage>1101</lpage>.</citation>
</ref>
<ref id="bibr26-0267659112456894">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mulla</surname><given-names>H</given-names></name>
<name><surname>McCormack</surname><given-names>P</given-names></name>
<name><surname>Lawson</surname><given-names>G</given-names></name>
<name><surname>Firmin</surname><given-names>RK</given-names></name>
<name><surname>Upton</surname><given-names>DR</given-names></name>
</person-group>. <article-title>Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation</article-title>. <source>Anesthesiology</source> <year>2003</year>; <volume>99</volume>: <fpage>275</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr27-0267659112456894">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhatt-Meht</surname><given-names>V</given-names></name>
<name><surname>Annich</surname><given-names>G</given-names></name>
</person-group>. <article-title>Sedative clearance during extracorporeal membrane oxygenation</article-title>. <source>Perfusion</source> <year>2005</year>; <volume>20</volume>: <fpage>309</fpage>–<lpage>315</lpage>.</citation>
</ref>
<ref id="bibr28-0267659112456894">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geiduschek</surname><given-names>JM</given-names></name>
<name><surname>Lynn</surname><given-names>AM</given-names></name>
<name><surname>Bratton</surname><given-names>SL</given-names></name>
<etal/>
</person-group>. <article-title>Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation</article-title>. <source>Crit Care Med</source> <year>1997</year>; <volume>25</volume>: <fpage>360</fpage>–<lpage>364</lpage>.</citation>
</ref>
<ref id="bibr29-0267659112456894">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thiara</surname><given-names>A.P.</given-names></name>
<name><surname>Hoel</surname><given-names>TN</given-names></name>
<name><surname>Kristiansen</surname><given-names>F</given-names></name>
<name><surname>Karlsen</surname><given-names>HM</given-names></name>
<name><surname>Fiane</surname><given-names>AE</given-names></name>
<name><surname>Svennevig</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Evaluation of oxygenators and centrifugal pumps for long-term pediatric extracorporeal membrane oxygenation</article-title>. <source>Perfusion</source> <year>2007</year>; <volume>22</volume>: <fpage>323</fpage>–<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr30-0267659112456894">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yliruusi</surname><given-names>JK</given-names></name>
<name><surname>Uotila</surname><given-names>JA</given-names></name>
<name><surname>Kristoffersson</surname><given-names>ER</given-names></name>
</person-group>. <article-title>Effect of flow rate and type of i.v. container on adsorption of diazepam to i.v. administration systems</article-title>. <source>Am J Hosp Pharm</source> <year>1986</year>; <volume>43</volume>: <fpage>2795</fpage>–<lpage>2799</lpage>.</citation>
</ref>
<ref id="bibr31-0267659112456894">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tarvainen</surname><given-names>T</given-names></name>
<name><surname>Svarfvar</surname><given-names>B</given-names></name>
<name><surname>Akerman</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Drug release from a porous ion-exchange membrane in vitro</article-title>. <source>Biomaterials</source> <year>1999</year>; <volume>20</volume>: <fpage>2177</fpage>–<lpage>2183</lpage>.</citation>
</ref>
<ref id="bibr32-0267659112456894">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>W</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<name><surname>Wu</surname><given-names>L</given-names></name>
<name><surname>Tian</surname><given-names>Y</given-names></name>
<name><surname>Feng</surname><given-names>S</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Determination of dexmedetomidine in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a pharmacokinetic study</article-title>. <source>J Pharm Biomed Anal</source> <year>2009</year>; <volume>50</volume>: <fpage>897</fpage>–<lpage>904</lpage>.</citation>
</ref>
<ref id="bibr33-0267659112456894">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>JH</given-names></name>
<name><surname>Truog</surname><given-names>RD</given-names></name>
<name><surname>Orav</surname><given-names>EJ</given-names></name>
<name><surname>Scavone</surname><given-names>JM</given-names></name>
<name><surname>Hershenson</surname><given-names>MB</given-names></name>
</person-group>. <article-title>Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation</article-title>. <source>Anesthesiology</source> <year>1990</year>; <volume>73</volume>: <fpage>1136</fpage>–<lpage>1140</lpage>.</citation>
</ref>
<ref id="bibr34-0267659112456894">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tobias</surname><given-names>JD</given-names></name>
<name><surname>Berkenbosch</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Initial experience with dexmedetomidine in paediatric-aged patients</article-title>. <source>Paediatr Anaesth</source> <year>2002</year>; <volume>12</volume>: <fpage>171</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr35-0267659112456894">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Preston</surname><given-names>TJ</given-names></name>
<name><surname>Hodge</surname><given-names>AB</given-names></name>
<name><surname>Riley</surname><given-names>JB</given-names></name>
<name><surname>Leib-Sargel</surname><given-names>C</given-names></name>
<name><surname>Nicol</surname><given-names>KK</given-names></name>
</person-group>. <article-title>In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit</article-title>. <source>J Extra Corpor Technol</source> <year>2007</year>; <volume>39</volume>: <fpage>234</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr36-0267659112456894">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wildschut</surname><given-names>ED</given-names></name>
<name><surname>Ahsman</surname><given-names>MJ</given-names></name>
<name><surname>Allegaert</surname><given-names>K</given-names></name>
<name><surname>Mathot</surname><given-names>RA</given-names></name>
<name><surname>Tibboel</surname><given-names>D</given-names></name>
</person-group>. <article-title>Determinants of drug absorption in different ECMO circuits</article-title>. <source>Intensive Care Med</source> <year>2010</year>; <volume>36</volume>: <fpage>2109</fpage>–<lpage>2116</lpage>.</citation>
</ref>
<ref id="bibr37-0267659112456894">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>AH</given-names></name>
<name><surname>Hardison</surname><given-names>DC</given-names></name>
<name><surname>Worden</surname><given-names>CR</given-names></name>
<name><surname>Fleming</surname><given-names>GM</given-names></name>
<name><surname>Taylor</surname><given-names>MB</given-names></name>
</person-group>. <article-title>Acute renal failure during extracorporeal support in the pediatric cardiac patient</article-title>. <source>ASAIO J</source> <year>2009</year>; <volume>55</volume>: <fpage>412</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr38-0267659112456894">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Swaniker</surname><given-names>F</given-names></name>
<name><surname>Bartlett</surname><given-names>R</given-names></name>
</person-group>. <article-title>Incidence and outcome of renal failure in adult ECMO patients</article-title>. <source>ASAIO</source> <year>2001</year>; <volume>47</volume>: <fpage>145</fpage>.</citation>
</ref>
<ref id="bibr39-0267659112456894">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wildschut</surname><given-names>ED</given-names></name>
<name><surname>Ahsman</surname><given-names>MJ</given-names></name>
<name><surname>Houmes</surname><given-names>RJ</given-names></name>
<etal/>
</person-group>. <article-title>Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO)</article-title>. <source>Curr Drug Metab</source> <year>2012</year>; <volume>13</volume>: <fpage>767</fpage>–<lpage>777</lpage>.</citation>
</ref>
<ref id="bibr40-0267659112456894">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Varghese</surname><given-names>JM</given-names></name>
<name><surname>Roberts</surname><given-names>JA</given-names></name>
<name><surname>Lipman</surname><given-names>J</given-names></name>
</person-group>. <article-title>Pharmacokinetics and pharmacodynamics in critically ill patients</article-title>. <source>Curr Opin Anaesthesiol</source> <year>2010</year>; <volume>23</volume>: <fpage>472</fpage>–<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr41-0267659112456894">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>GD</given-names></name>
<name><surname>Lynn</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Optimizing pediatric dosing: a developmental pharmacologic approach</article-title>. <source>Pharmacotherapy</source> <year>2009</year>; <volume>29</volume>: <fpage>680</fpage>–<lpage>690</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>